The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BEVATEM: Phase II single-center study of bevacizumab in combination with temozolomide in patients (pts) with first-line metastatic uveal melanoma (MUM): First-step results.
Sophie Piperno-Neumann
Research Funding - Roche
Vincent Servois
No relevant relationships to disclose
Francois-Clement Bidard
No relevant relationships to disclose
Pascale Mariani
No relevant relationships to disclose
Corine Plancher
No relevant relationships to disclose
Bernard Asselain
No relevant relationships to disclose
Nora Vago-Ady
Employment or Leadership Position - Roche
Laurence Desjardins
No relevant relationships to disclose